<DOC>
	<DOCNO>NCT00806806</DOCNO>
	<brief_summary>Given single perioperative injection , SKY0402 could provide adequate , continuous , extend pain relief could greatly simplify postoperative pain management , reduce need repeat administration , minimize episode breakthrough pain .</brief_summary>
	<brief_title>Evaluate Onset Action SKY0402 Following Local Infiltration Healthy Volunteers</brief_title>
	<detailed_description>Subjects give either SKY0402 placebo response noxious stimulus , time onset record .</detailed_description>
	<mesh_term>Pain , Postoperative</mesh_term>
	<criteria>Subjects eligible study entry meet follow criterion : Male female , age least 18 year 55 year . Body mass index ( BMI ) within range 20.0 30.0 kg/m2 , inclusive . Applies female : Female subject childbearing potential nonsterilized male sexual partner must agree use hormonal contraceptive , barrier contraceptive additional spermicide , intrauterine device begin &gt; 30 day prior first dose continue &gt; 7 day end study . Female subject postmenopausal must postmenopausal &gt; 1 year wish use contraceptive . Good general health , evidence lack significantly abnormal finding medical history screen assessment . Pain intensity score &gt; 30 mm VAS incision application 18 % acetic acid solution nontreated skin ( i.e. , infiltrated test control article ) Screening . Able willing comply study visit procedure , include return scheduled second treatment visit . Able speak , read , understand language ICF , study questionnaire , instrument use collect subjectreported outcome , order enable accurate appropriate response pain scale require study assessment . Willing capable provide write informed consent . A subject eligible study meet follow criterion : A history hypersensitivity amide type local anesthetic . Pregnancy , nursing , plan become pregnant course study . Any current condition might interfere pain assessment , include current pain . Conditions skin neurological abnormality might alter pain sensitivity . These include excessive scarring , burn , skin graft , trauma . Tattoos permit . A history keloid formation . A coagulopathy use medication might enhance bleeding . Use follow medication within time specify study drug administration : Longacting opioid mediation within 3 day . Any opioid medication within 24 hour . Any analgesic medication within 12 hour . Consumption alcohol within 24 hour either treatment visit . Any condition , opinion Investigator , render subject unsuitable participation study . NOTE : The specific reason ( ) exclusion document Screening Log . Administration investigational drug within 30 day 5 elimination halflives investigational drug , whichever longer , prior study drug administration , plan administration another investigational product procedure subject 's participation study . Minor deviation eligibility criterion permit approved Pacira Medical Monitor agreement Investigator prior dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>pain management</keyword>
	<keyword>postoperative</keyword>
</DOC>